According to filings with the U.S. Securities and Exchange Commission, Akari Therapeutics is raising $2,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Rachelle Jacques played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akaris lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity. Akaris pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), as well as pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA).

To learn more about Akari Therapeutics, visit http://www.akaritx.com/

Contact:
Rachelle Jacques, President and Chief Executive Officer
646-350-0702
https://www.linkedin.com/in/rachellejacques/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.